ERBB2 and breast cancer: Regardless of the PAM50 Luminal intrinsic subtype, PFS remained better in patients with HR-positive BC: 10.6 months (95% CI, 4.1–14.8) in Luminal B, 8.2 months (95% CI, 2.2–24.1) in Luminal A, 3.8 months (95% CI, 2.1–10.9) in HER2-enriched, and 6.0 months (95% CI, 1.7–11.2) in normal-like [75].